FDA approve new dosage of Suboxone (Reckitt Benckiser) for treating Opioid Dependence

The FDA has approved 4 mg and 12 mg doses of Suboxone (buprenorphine and naloxone) sublingual film, from Reckitt Benckiser, for maintenance treatment of Opioid Dependence, also known as prescription opioid painkiller and heroin addiction. Reckitt Benckiser developed these strengths in an effort to help mitigate the risk of unintentional multi-dose pediatric exposure, which is a major public health concern associated with medications. Having the individually wrapped, unit-dose packaging of Suboxone sublingual film in more dosage choices provides healthcare professionals with more flexible, customizable treatment options, and may help reduce the risk of children accessing inappropriately stored medication. Suboxone sublingual film was approved by the FDA in August 2010.